Showing results (1601-1610 of 1,711) with videos related to
Sort By:
Pageof 172
Circulation|October 28, 2021
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesMartha Gulati, Phillip D Levy, Debabrata Mukherjee, et al.American Heart Journal|June 4, 2014
Proceedings from Duke resistant hypertension think tankSreekanth Vemulapalli, Jamy Ard, George L Bakris, et al.Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.Journal of the American College of Cardiology|June 20, 2020
Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography SubstudyRaj R Makkar, Philipp Blanke, Jonathon Leipsic, et al.Nature Reviews. Cardiology|June 13, 2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.Journal of the American College of Cardiology|January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeVera A Bittner, Michael Szarek, Philip E Aylward, et al.The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.Circulation|May 24, 2019
Effect of Alirocumab on Mortality After Acute Coronary SyndromesPhilippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, et al.JAMA|November 4, 2004
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement InitiativeDeepak L Bhatt, Matthew T Roe, Eric D Peterson, et al.Pageof 172